Cyclerion Therapeutics Inc (CYCN)

[Monksdream]

CYCN under $4

[Monksdream]

CYCN 10 Q due MONDAY 3/3

[glenn1919]

CYCN................................................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783

[georgie18]

CYCN...$6.05...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 31425

Monday, February 03, 2025 2:09:38 PM

Post#
31429
of 31433
CYCN...$5.68...HOD...🥳...off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 673136

Monday, February 03, 2025 1:54:57 PM

Post#
673150
of 673155
CYCN...$5.13 On the breakout...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 31398

Monday, February 03, 2025 12:30:04 PM

Post#
31405
of 31424
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...

georgie18

Member Level
Re: georgie18 post# 673098

Monday, February 03, 2025 12:09:45 PM

Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

[georgie18]

CYCN...$5.68...HOD...🥳...off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 673136

Monday, February 03, 2025 1:54:57 PM

Post#
673150
of 673155
CYCN...$5.13 On the breakout...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 31398

Monday, February 03, 2025 12:30:04 PM

Post#
31405
of 31424
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...

georgie18

Member Level
Re: georgie18 post# 673098

Monday, February 03, 2025 12:09:45 PM

Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

[georgie18]

CYCN...$5.13 On the breakout...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: georgie18 post# 31398

Monday, February 03, 2025 12:30:04 PM

Post#
31405
of 31424
CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...

georgie18

Member Level
Re: georgie18 post# 673098

Monday, February 03, 2025 12:09:45 PM

Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

[georgie18]

CYCN...$4.97...Hit $5.20...HOD...🥳...off my $3.24Alert...

georgie18

Member Level
Re: georgie18 post# 673098

Monday, February 03, 2025 12:09:45 PM

Post#
673129
of 673135
CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

[georgie18]

CYCN...$4.72...Off my $3.24 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 31270

Monday, February 03, 2025 8:27:19 AM

Post#
31363
of 31397
CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

[glenn1919]

CYCN......................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783

[tw0122]

One more round $4.56 + 16% 2m floater take profits  otw up $4.70s

[georgie18]

CYCN...$4.58...🥳

georgie18

Member Level
Re: georgie18 post# 672920

Friday, January 31, 2025 9:55:17 AM

Post#
672926
of 673097
CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

[georgie18]

CYCN...$4.47...HOD...🥳...2 Million Range Float...

georgie18

Member Level
Re: tw0122 post# 31264

Friday, January 31, 2025 9:44:57 AM

Post#
31265
of 31268
CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

[georgie18]

CYCN...$4.09...Off my $3.24 Alert...Price catching up to the News here...🥳

georgie18

Member Level
Re: georgie18 post# 670922

Thursday, January 30, 2025 8:01:17 PM

Post#
672876
of 672918
CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

[tw0122]

Ring the register $4.07$$$$

[glenn1919]

CYCN.......................................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783

[georgie18]

CYCN...$3.80...🥳...Off my $3.24 Alert...

georgie18

Member Level
Re: None

Thursday, January 09, 2025 9:18:16 AM

Post#
73
of 74
CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

[glenn1919]

cycn.........................................................a/h

[georgie18]

CYCN...$3.24...🥳... https://schrts.co/BZqjIquT ...Float in 2 Million range...CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The Company is leveraging its legacy soluble guanylate cyclase (sGC) stimulator assets to generate near-term revenues which will be used to implement its strategic building plan without near-term dilution.

“These agreements demonstrate Cyclerion’s progress in maximizing its legacy asset value while redirecting resources toward acquiring potential new assets,” said Regina Graul, Ph.D., President and Chief Executive Officer of Cyclerion. “These newly finalized agreements, combined with our significant reduction of operating expenses, enable the focused use of our capital to support our anticipated pipeline build in the central nervous system (CNS) space. Concurrently, we plan to raise capital, as needed, to fund our product plans to create value for shareholders and patients.” Graul continued, “Cyclerion’s diligence team, comprised of committed external experts in their respective fields, is currently in advanced stages of conducting promising asset evaluations, which we believe have the potential to be the new foundation for Cyclerion.”

Cyclerion and Akebia have re-negotiated a mutually beneficial amendment to their exclusive license agreement for praliciguat, a systemic sGC stimulator. Under the new license amendment with Akebia, Cyclerion will receive $1.75 million in upfront and near-term payments. In addition, Akebia will assume responsibility for all intellectual property expenses associated with praliciguat after Q1 2025. In 2021, Akebia paid a $3.0 million upfront payment to the Company upon signing of the license agreement, and the Company is eligible to receive additional milestone cash payments of up to approximately $560 million in total potential future development, regulatory, and commercialization milestone payments for praliciguat. In exchange for a reduction in certain development milestone payments, Cyclerion is eligible to receive certain higher, tiered, sales-based royalties ranging from mid-single-digits to twenty percent.

Cyclerion has also entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states. Under the terms of the agreement, the potential partner has exclusive rights to evaluate olinciguat during the option period. During the option period, the grantee has assumed responsibility for all ongoing intellectual property-related expenses associated with olinciguat.

As part of its strategic initiatives, Cyclerion previously announced a definitive agreement for the sale of its CNS assets zagociguat and CY3018 to Tisento Therapeutics in May 2023 for an $8 million cash payment and a 10% equity stake in Tisento. The amended agreement for praliciguat, and if the option for olinciguat is exercised, would represent the likely final steps in the monetization of Cyclerion’s historical portfolio. Cyclerion believes it is well positioned for the next phase in its overall strategy, to bring in new CNS assets to rebuild the pipeline.

[LowFloatLopes]

That's usually exactly what I do sometimes I'll gamble though and stay in longer like I did today :) good strategy 👍🏼

[Strukture]

I just sell the top of the rips buy the dips so long as the trend stays bullish if it goes para after i sell thats ok too

[LowFloatLopes]

Right on cue lol 

[LowFloatLopes]

IM still holding from that past.. I'm feeling a pop 29 or 10 in the next hour

[trader59]

Automated wash trading, brazen manipulation of the PPS. The O/S is 2.7M shares, which means that each and every share issued and outstanding has changed hands, on average, over 40 times today. Once they turn their computers off, folks will be trapped with grossly overpriced bags.

[Strukture]

I was out at 8.20 on that push for a quick 30%

[tw0122]

Gave you green light alert at $4s premarket ..lol on the monthly chart all green with 3 hits the 3rd being today 

[PonkenPlonken]

mhmm

[LowFloatLopes]

Got a sale set at 9.70

[LowFloatLopes]

6.45 here :)

[Strukture]

Re loaded at 6.30 halted up back at HOD 8.40

[ecmoney]

Halted again $8.39

Ec

[LowFloatLopes]

In at $4.30 out at $7.90 in 15 mins lol 

[Strukture]

CYCN Boom

[ecmoney]

Halted at $6

Rc

[Invest-in-America]

CYCN: Could NOT find any PR's nor otherwise NEWS anywhere to support this??? (Just the MM machines & algos???)

[ecmoney]

Thinking about jumping back in around $5


Ec

[glenn1919]

CYCN.....................................$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

[ecmoney]

I’m out

Easy 300%

Ec

[tw0122]

$6.43 + 300% going to cash out now 

[tw0122]

$5.49'+ 250%

[tw0122]

Party over here also $5.05 + 210%

[tw0122]

CYCN $4.88 + 200% 

[tw0122]

CYCN 2.62 +92% flip out time 

[glenn1919]

cycn.......................................................https://stockcharts.com/h-sc/ui?s=cycn&p=D&yr=0&mn=2&dy=12&id=p84071410134


...............................nice bounce & volume..................................................

[tw0122]

2.49 +'83%

[tw0122]

CYCN $2.26 + 70%

[glenn1919]

CYCN.................................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783

[glenn1919]

CYCN.................https://stockcharts.com/h-sc/ui?s=CYCN&p=W&b=5&g=0&id=p86431144783

[tw0122]

$2.40- $2.65 first line of resistance breaks solid $3.16 next 

[tw0122]

Mini pump

[Banjo50]

It should be five cents. I bid five cents.